<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006093</url>
  </required_header>
  <id_info>
    <org_study_id>19-060</org_study_id>
    <nct_id>NCT04006093</nct_id>
  </id_info>
  <brief_title>Apixaban in Subjects With Peritoneal Dialysis</brief_title>
  <acronym>ApiDP</acronym>
  <official_title>Pharmacokinetics of Apixaban in Subjects With End-stage Renal Disease Treated With Peritoneal Dialysis: the ApiDP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the pharmacokinetics of a single oral dose
      of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal
      renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with chronic renal disease treated with peritoneal dialysis and participants
      with normal renal function are hospitalized for three days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups of participants will receive one single-dose of 5 mg of apixaban: the first group of participants with a normal renal function, the second group contains participants with end-stage renal disease treated with peritoneal dialysis.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apixaban area Under the curve</measure>
    <time_frame>Day 3</time_frame>
    <description>Measurement of apixaban plasma concentrations at different times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apixaban maximum plasma concentration</measure>
    <time_frame>Day 3</time_frame>
    <description>Measurement of apixaban plasma concentrations at different times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-Xa activity</measure>
    <time_frame>Hour 0, Hour 3, Hour 9 and Hour 72</time_frame>
    <description>anti-Xa activity plasma measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TP activity</measure>
    <time_frame>Hour 0, Hour 3, Hour 9 and Hour 72</time_frame>
    <description>TP activity plasma measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCA activity</measure>
    <time_frame>Hour 0, Hour 3, Hour 9 and Hour 72</time_frame>
    <description>TCA activity plasma measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apixaban urinary elimination</measure>
    <time_frame>Day 3</time_frame>
    <description>Measurement of apixaban urinary concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apixaban maximum peritoneal concentration</measure>
    <time_frame>day 3</time_frame>
    <description>Measurement of apixaban peritoneal fluid concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>participants with normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>participants with end-stage renal disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban Oral</intervention_name>
    <description>one Tablet 5mg</description>
    <arm_group_label>participants with end-stage renal disease</arm_group_label>
    <arm_group_label>participants with normal renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant with 21&lt;BMI&lt;40

          -  French participant

          -  Participant able to consent

          -  Participant with social insurance

          -  Participant on peritoneal dialysis for at least 3 months with end-stage renal disease
             treated

        Exclusion Criteria:

          -  Participant with hypersensibility reactions to apixaban

          -  Participant with a history of major bleeding

          -  Participant already on anticoagulant

          -  Participant on non-stearoid anti-inflammatory at anti-inflammatory dosage &gt; 300 mg

          -  Participant on potent inhibitors of CYP 3A4 and P-gp

          -  Participant on inducers of CYP3A4 and P-sp

          -  Participant with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment

          -  Participant receiving or having received antibiotic treatment within 14 days prior to
             study

          -  Pregnant or lactating women

          -  Participant with known hypersensitivity reactions to icodextrin

          -  Participant not supporting an intraperitoneal volume of 2 liters (only participant
             with peritoneal dialysis)

          -  Participant with &quot;Normal renal function&quot; with glomerular filtration rate &lt; 90 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laure Peyro-Saint-Paul, PharmD</last_name>
    <phone>33231065342</phone>
    <email>peyrosaintpaul-l@chu-caen.fr</email>
  </overall_contact>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

